SCHEMBL209313

SCHEMBL209313

O=C(c1ccc(-c2cc(Cl)c(CC3CCN(C4CCOCC4)C3=O)c(Cl)c2)cc1)N1CCC(C(F)(F)F)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.38
NPSR1 Q6W5P4 1/20 0.37
ERN1 O75460 2/20 0.37
NAMPT P43490 1/20 0.36
HDAC4 P56524 2/20 0.36
KCNH2 Q12809 2/20 0.35
L3MBTL3 Q96JM7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MET P08581 1/20 0.35
HTR2B P41595 1/20 0.35
MCHR1 Q99705 1/20 0.35
PKM P14618 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
ADRA2C P18825 1/20 0.35
CHRM3 P20309 1/20 0.35
DRD4 P21917 1/20 0.35
SLC6A2 P23975 1/20 0.35
HRH2 P25021 1/20 0.35
SLC6A4 P31645 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL209312 1.00 HRH3 (0.38) HRH3NPSR1ERN1NAMPTHDAC4
SCHEMBL3125447 0.92 HRH3 (0.37) HRH3NAMPTMETHTR2BSPR
SCHEMBL3127709 0.92 HRH3 (0.37) HRH3NAMPTMETHTR2BSPR
SCHEMBL3127712 0.92 HRH3 (0.37) HRH3NAMPTMETHTR2BSPR
SCHEMBL208372 0.91 HSD11B1 (0.41) NAMPTL3MBTL3L3MBTL1METHTR2B
SCHEMBL208557 0.91 HTR2B (0.37) HRH3NAMPTHDAC4METHTR2B
SCHEMBL208929 0.91 HTR2B (0.37) HRH3NAMPTHDAC4METHTR2B
SCHEMBL208558 0.91 HTR2B (0.37) HRH3NAMPTHDAC4METHTR2B
SCHEMBL208559 0.91 HTR2B (0.37) HRH3NAMPTHDAC4METHTR2B
SCHEMBL209661 0.90 PKM (0.44) HRH3NPSR1ERN1METPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP claimed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US claimed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US claimed
EP-2016047-B1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-08-28 EP disclosed
US-8088776-B2 Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2012-01-03 US disclosed
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156571-A1 BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 HRH3 1964/4885NPSR1 1573/4885ERN1 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.